Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
FDA Approved Phase II/III Clinical Study of KPG-121 in Combination with Abiraterone as a First Line Treatment for mCRPC 2024-06-05 19:00
Pierre Fabre Laboratories Announce IND Filing for PFL-002/VERT-002, a Potential Treatment for Patients with Solid Tumors, Including Non-Small Cell Lung Cancer with MET Alterations 2024-06-05 15:15
GC Genome Highlights Promising New Approach for Non-invasive Colorectal Cancer Detection at ASCO 2024 2024-06-05 14:00
ASG Pioneers Development of novel inhaled drugs and Accelerates R&D Progress 2024-06-05 12:30
Live from ASCO 2024 | Oral Report Released Latest Data of Olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3% 2024-06-05 11:46
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WM 2024-06-05 11:31
Dalton Pharma Services Invests in Robotic Aseptic Powder Fill-Finish Line from 3P innovation 2024-06-05 10:00
CARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO 2024-06-04 20:50
GCBP Sponsors 2024 Spring Symposium for KASBP and Present Research Findings 2024-06-04 13:00
Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety 2024-06-04 12:51
Fapon Biopharma Announces a Safer Immunotherapy for Cancers 2024-06-04 09:42
RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88 2024-06-04 09:38
Minghui Pharmaceutical Presents Phase 1/2 Clinical Data of MHB088C (B7-H3 ADC) as Monotherapy for the Treatment of Patients with Recurrent or Metastatic Solid Tumors at the 2024 ASCO Annual Meeting 2024-06-03 21:30
Formosa Laboratories Completes the Acquisition of Synchem to Expand North American CDMO Footprint 2024-06-03 13:01
Leads Biolabs' Innovative Cancer Treatment LBL-024, an Anti-PDL1/4-1BB Bispecific Antibody Achieved Outstanding Phase II Results, Has Been Presented in Clinical Science Symposium at 2024 ASCO Annual Meeting. 2024-06-03 10:57
Alphamab Oncology Presented Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meeting 2024-06-03 10:17
Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer at 2024 ASCO Annual Meeting 2024-06-03 09:44
Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer and Gastric Cancer 2024-06-03 09:35
Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis 2024-06-03 09:14
Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting 2024-06-02 13:19
1 30 31 32 33 34 412